Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_assertion type Assertion NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_head.
- NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_assertion description "[Molecular therapeutic approaches, for example, those directed against the fusion protein BCR-ABL with ABL-tyrosine kinase inhibitor, are on the way to creating a new avenue for the treatment of ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_provenance.
- NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_assertion evidence source_evidence_literature NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_provenance.
- NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_assertion SIO_000772 11049022 NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_provenance.
- NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_assertion wasDerivedFrom befree-2016 NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_provenance.
- NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_assertion wasGeneratedBy ECO_0000203 NP298417.RA9nW_UzJ4diPY4SXyZxKV_1NH5nhp4ZKySk9HH2_pCPI130_provenance.